Warwick Butt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Warwick Butt has a total of 242 co-authors. Here are the top co-authors by number of shared publications:
- Ben Gelbart
Paediatric Intensive Care Unit, Murdoch Children’s Research Institute, University of Melbourne, Parkville, VIC, Australia
5 shared publications - Luregn Jan Schlapbach
Department of Intensive Care and Neonatology, University Children’s Hospital Zurich, University of Zurich
5 shared publications Claire Sherring
Children’s Intensive Care Research Program, Child Health Research Centre, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia
4 shared publications- Kristen Gibbons
Children's Intensive Care Research Program, Child Health Research Centre, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia
4 shared publications - Roberto Chiletti
Intensive Care Unit, Royal Children’s Hospital, Melbourne, VIC, Australia
4 shared publications - Sainath Raman
University of Queensland Child Health Research Centre, South Brisbane, Queensland, Australia
4 shared publications
Latest Publications
- 21 October 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
Hemodynamic Patterns Relative to Vasopressin Initiation and Subsequent Septic Shock Progression in Children: A Retrospective Cohort, 2020–2023
Objectives: To describe the hemodynamic patterns associated with starting vasopressin in children with septic shock and to compare the early patterns based on subsequent progression of shock. Design: Retrospective cohort (2020–2023) study. Setting: Single-center, tertiary PICU in Australia. Patients: Children younger than 18 years with septic shock. Interventions: None. Measurements and Main Results: Hemodynamic variables collected at 1-minute intervals during a 1-hour observation period after starting vasopressin infusion were reviewed and collated according to whether shock subsequently progressed in the following 5 hours. In a cohort of 30 children (median age, 9 yr [interquartile range, 2–14 yr]), eight had shock progression, which was defined by echocardiography, lactate, and use of extracorporeal support. Cases with subsequent shock progression, as opposedto not, had an associated higher Phoenix score (7 [7–8] vs. 6 [5–6]; p = 0.01). The vasopressin starting dose in the shock vs. nonshock progression groups was 0.03 U/kg/hr (0.02–0.06 U/kg/hr) vs. 0.02 U/kg/hr (0.02–0.04 U/kg/hr; p = 0.72). We failed to find an association between ventricular dysfunction at baseline and the shock progression group vs. no shock progression (4/6 vs. 7/18; mean difference, 28%; 95% CI, –16% to 71%; p = 0.36). In the shock progression group, earlier pulse pressure continued on a decreasing trajectory following vasopressin initiation, despite increasing systolic and diastolic blood pressures. In those without shock progression, pulse pressure increased marginally. The difference between groups in the median pulse pressures during the observation period was 7.5 mm Hg. Conclusions: In this hypothesis-generating, retrospective study of children with septic shock treated with vasopressin, subsequent shock progression was associated with early decreasing pulse pressure. Further studies are needed to test whether early changes in pulse pressure after starting vasopressin can be used as a potential marker of subsequent shock progression.
- 21 October 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
Hemodynamic Patterns Relative to Vasopressin Initiation and Subsequent Septic Shock Progression in Children: A Retrospective Cohort, 2020–2023
Objectives: To describe the hemodynamic patterns associated with starting vasopressin in children with septic shock and to compare the early patterns based on subsequent progression of shock. Design: Retrospective cohort (2020–2023) study. Setting: Single-center, tertiary PICU in Australia. Patients: Children younger than 18 years with septic shock. Interventions: None. Measurements and Main Results: Hemodynamic variables collected at 1-minute intervals during a 1-hour observation period after starting vasopressin infusion were reviewed and collated according to whether shock subsequently progressed in the following 5 hours. In a cohort of 30 children (median age, 9 yr [interquartile range, 2–14 yr]), eight had shock progression, which was defined by echocardiography, lactate, and use of extracorporeal support. Cases with subsequent shock progression, as opposedto not, had an associated higher Phoenix score (7 [7–8] vs. 6 [5–6]; p = 0.01). The vasopressin starting dose in the shock vs. nonshock progression groups was 0.03 U/kg/hr (0.02–0.06 U/kg/hr) vs. 0.02 U/kg/hr (0.02–0.04 U/kg/hr; p = 0.72). We failed to find an association between ventricular dysfunction at baseline and the shock progression group vs. no shock progression (4/6 vs. 7/18; mean difference, 28%; 95% CI, –16% to 71%; p = 0.36). In the shock progression group, earlier pulse pressure continued on a decreasing trajectory following vasopressin initiation, despite increasing systolic and diastolic blood pressures. In those without shock progression, pulse pressure increased marginally. The difference between groups in the median pulse pressures during the observation period was 7.5 mm Hg. Conclusions: In this hypothesis-generating, retrospective study of children with septic shock treated with vasopressin, subsequent shock progression was associated with early decreasing pulse pressure. Further studies are needed to test whether early changes in pulse pressure after starting vasopressin can be used as a potential marker of subsequent shock progression.
- 14 September 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
Secondary analysis of the 2021–2023 Sepsis Epidemiology in Australian and New Zealand Children Observational Dataset: Association Between Presenting Venous Lactate Concentration and 72-Hour Outcomes
Objectives: In pediatric patients with sepsis, we hypothesized that the initial venous lactate concentration would be associated with subsequent need for extracorporeal life support (ECLS) or death within 72 hours. Design: A planned secondary analysis of data from the multicenter, two-country Sepsis Epidemiology Emergency Departments (SENTINEL) study, collected 2021–2023. Setting: Acute care hospitals in Australia and New Zealand. Patients: SENTINEL participants were children of 0 to less than 18 years with suspected sepsis admitted to the hospital through 11 emergency departments. Interventions: None. Measurements and Main Results: We used the initial venous lactate concentration (sampling within 4 hr of hospital arrival) as an explanatory variable for subsequent need for ECLS or death within 72 hours. In 4806 children, with a median (interquartile range [IQR]) age of 1.9 years (IQR, 0.2–6.7 yr), 2651 children (55.2%) were males, and 33 children (0.7%) received ECLS or died within 72 hours. The best-performing initial lactate concentration associated with ECLS or death within 72 hours was 3.5 mmol/L and was observed in 745 of 4806 children (15.5%), including 24 of 33 children requiring ECLS or who died within 72 hours. As a “diagnostic” test, lactate greater than or equal to 3.5 mmol/L had sensitivity (95% CI) of 72.7% (95% CI, 54.5–86.7%), specificity of 84.9% (95% CI, 83.9–85.9%), and area under the receiver-operating characteristics curve of 0.79 (95% CI, 0.71–0.87) for ECLS or death within 72 hours, which are in the acceptable-to-fair category. That is, a 4-hour lactate concentration greater than or equal to 3.5 mmol/L takes the pre- to posttest probability of ECLS/death from 0.7% to 3.2%. Conclusions: In this secondary analysis of the 2021–2023 SENTINEL dataset, we have found that at the time children are hospitalized with suspected community-acquired sepsis, an initial venous lactate greater than or equal to 3.5 mmol/L has an acceptable-to-fair association with subsequent need for ECLS, or death, within 72 hours. Clinicians will need to decide whether such testing on its own is useful in decision-making.
- 14 September 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
Secondary analysis of the 2021–2023 Sepsis Epidemiology in Australian and New Zealand Children Observational Dataset: Association Between Presenting Venous Lactate Concentration and 72-Hour Outcomes
Objectives: In pediatric patients with sepsis, we hypothesized that the initial venous lactate concentration would be associated with subsequent need for extracorporeal life support (ECLS) or death within 72 hours. Design: A planned secondary analysis of data from the multicenter, two-country Sepsis Epidemiology Emergency Departments (SENTINEL) study, collected 2021–2023. Setting: Acute care hospitals in Australia and New Zealand. Patients: SENTINEL participants were children of 0 to less than 18 years with suspected sepsis admitted to the hospital through 11 emergency departments. Interventions: None. Measurements and Main Results: We used the initial venous lactate concentration (sampling within 4 hr of hospital arrival) as an explanatory variable for subsequent need for ECLS or death within 72 hours. In 4806 children, with a median (interquartile range [IQR]) age of 1.9 years (IQR, 0.2–6.7 yr), 2651 children (55.2%) were males, and 33 children (0.7%) received ECLS or died within 72 hours. The best-performing initial lactate concentration associated with ECLS or death within 72 hours was 3.5 mmol/L and was observed in 745 of 4806 children (15.5%), including 24 of 33 children requiring ECLS or who died within 72 hours. As a “diagnostic” test, lactate greater than or equal to 3.5 mmol/L had sensitivity (95% CI) of 72.7% (95% CI, 54.5–86.7%), specificity of 84.9% (95% CI, 83.9–85.9%), and area under the receiver-operating characteristics curve of 0.79 (95% CI, 0.71–0.87) for ECLS or death within 72 hours, which are in the acceptable-to-fair category. That is, a 4-hour lactate concentration greater than or equal to 3.5 mmol/L takes the pre- to posttest probability of ECLS/death from 0.7% to 3.2%. Conclusions: In this secondary analysis of the 2021–2023 SENTINEL dataset, we have found that at the time children are hospitalized with suspected community-acquired sepsis, an initial venous lactate greater than or equal to 3.5 mmol/L has an acceptable-to-fair association with subsequent need for ECLS, or death, within 72 hours. Clinicians will need to decide whether such testing on its own is useful in decision-making.
- Open Access
- 7 August 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 27 (10) , 1195-1206
Validation of SeptiCyte RAPID to Discriminate Sepsis From Noninfectious Systemic Inflammation in Critically Ill Children
OBJECTIVES: Biomarkers with adequate precision to rule-in/rule-out sepsis in children represent an unmet need. SeptiCyte RAPID is a point-of-care, U.S. Food and Drug Administration-cleared, host gene expression biomarker test for the determination of sepsis probability (reported in 1 hr as a SeptiScore) using a small-volume peripheral blood sample. We have previously reported on SeptiCyte RAPID performance in adults. Here we report a retrospective, noninterventional clinical validation study of SeptiCyte RAPID, as a sepsis diagnostic adjunct in children. DESIGN, SETTING, AND PATIENTS: Critically ill children ( n = 284), 1 month to 18 years old, admitted to PICUs, with or without suspected or documented infection, but all of whom met criteria for systemic inflammatory response syndrome (SIRS) and were enrolled at multiple clinical sites in the United States and Australia in four separate studies. INTERVENTIONS: None; SeptiCyte RAPID results were not used to guide patient treatment. MEASUREMENTS AND MAIN RESULTS: A combination of clinical adjudication and an independent panel of three physicians (Retrospective Physician Diagnosis [RPD]), blinded to SeptiCyte RAPID results, were used to retrospectively categorize patients into sepsis vs. noninfectious SIRS categories. Diagnostic performance of SeptiCyte RAPID for differentiating sepsis and noninfectious SIRS compared with RPD was measured using area under the curve (AUC), likelihood ratio, and a monotonic increase in probability of sepsis and increasing SeptiScores. Binomial logistic regression analysis was used to integrate clinical parameters in a model based on SeptiCyte RAPID. Higher SeptiScores correlated with higher probability of sepsis. SeptiCyte RAPID AUC for identifying sepsis in children ranged from 0.80 to 0.83. A model additionally integrating lactate, platelet number, mean arterial pressure, Pa co 2 , mechanical ventilation, weight, age, and leukocyte count increased SeptiCyte RAPID performance (AUC, 0.86; 95% CI, 0.85–0.87). CONCLUSIONS: SeptiCyte RAPID demonstrated similar performance characteristics in children to that previously reported for adults. Additional real world effectiveness studies are warranted to determine real-time clinical utility, patient benefits, and health economic impact.
- 7 August 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 27 (10) , 1195-1206
Open AccessValidation of SeptiCyte RAPID to Discriminate Sepsis From Noninfectious Systemic Inflammation in Critically Ill Children
OBJECTIVES: Biomarkers with adequate precision to rule-in/rule-out sepsis in children represent an unmet need. SeptiCyte RAPID is a point-of-care, U.S. Food and Drug Administration-cleared, host gene expression biomarker test for the determination of sepsis probability (reported in 1 hr as a SeptiScore) using a small-volume peripheral blood sample. We have previously reported on SeptiCyte RAPID performance in adults. Here we report a retrospective, noninterventional clinical validation study of SeptiCyte RAPID, as a sepsis diagnostic adjunct in children. DESIGN, SETTING, AND PATIENTS: Critically ill children ( n = 284), 1 month to 18 years old, admitted to PICUs, with or without suspected or documented infection, but all of whom met criteria for systemic inflammatory response syndrome (SIRS) and were enrolled at multiple clinical sites in the United States and Australia in four separate studies. INTERVENTIONS: None; SeptiCyte RAPID results were not used to guide patient treatment. MEASUREMENTS AND MAIN RESULTS: A combination of clinical adjudication and an independent panel of three physicians (Retrospective Physician Diagnosis [RPD]), blinded to SeptiCyte RAPID results, were used to retrospectively categorize patients into sepsis vs. noninfectious SIRS categories. Diagnostic performance of SeptiCyte RAPID for differentiating sepsis and noninfectious SIRS compared with RPD was measured using area under the curve (AUC), likelihood ratio, and a monotonic increase in probability of sepsis and increasing SeptiScores. Binomial logistic regression analysis was used to integrate clinical parameters in a model based on SeptiCyte RAPID. Higher SeptiScores correlated with higher probability of sepsis. SeptiCyte RAPID AUC for identifying sepsis in children ranged from 0.80 to 0.83. A model additionally integrating lactate, platelet number, mean arterial pressure, Pa co 2 , mechanical ventilation, weight, age, and leukocyte count increased SeptiCyte RAPID performance (AUC, 0.86; 95% CI, 0.85–0.87). CONCLUSIONS: SeptiCyte RAPID demonstrated similar performance characteristics in children to that previously reported for adults. Additional real world effectiveness studies are warranted to determine real-time clinical utility, patient benefits, and health economic impact.
- Open Access
- 27 March 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 27 (6) , 762-771
“In-Series” Continuous Renal Replacement Therapy and Therapeutic Plasma Exchange: Single-Center Retrospective Cohort, 2018–2022
OBJECTIVES: To describe our use and experience with an “in-series” approach for patients requiring both continuous renal replacement therapy (CRRT) as well as therapeutic plasma exchange (TPE). DESIGN: Retrospective review of case notes. SETTING: General and cardiac PICUs at the Royal Children’s Hospital in Melbourne, VIC, Australia. PATIENTS: Children (0–18 yr old) requiring both CRRT and TPE between 2018 and 2022. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Twelve children were successfully and safely treated with 32 TPE sessions and 38 CRRT sessions with our in-series CRRT and TPE setup using a total of 20 extracorporeal circuits and 11 additional plasma filters or hemofilters. This represents a reduction of 71% in standard circuit usage. CONCLUSIONS: Our approach to providing “in-series” CRRT and TPE used existing access and circuits, a single device, and resulted in efficient treatments, reduced infection risk, reduced exposure to circuits, less hemodilution, and less blood product use. Small potential cost and waste reductions were also achieved. This approach was performed safely with no unexpected adverse events.
- 27 March 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 27 (6) , 762-771
Open Access“In-Series” Continuous Renal Replacement Therapy and Therapeutic Plasma Exchange: Single-Center Retrospective Cohort, 2018–2022
OBJECTIVES: To describe our use and experience with an “in-series” approach for patients requiring both continuous renal replacement therapy (CRRT) as well as therapeutic plasma exchange (TPE). DESIGN: Retrospective review of case notes. SETTING: General and cardiac PICUs at the Royal Children’s Hospital in Melbourne, VIC, Australia. PATIENTS: Children (0–18 yr old) requiring both CRRT and TPE between 2018 and 2022. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Twelve children were successfully and safely treated with 32 TPE sessions and 38 CRRT sessions with our in-series CRRT and TPE setup using a total of 20 extracorporeal circuits and 11 additional plasma filters or hemofilters. This represents a reduction of 71% in standard circuit usage. CONCLUSIONS: Our approach to providing “in-series” CRRT and TPE used existing access and circuits, a single device, and resulted in efficient treatments, reduced infection risk, reduced exposure to circuits, less hemodilution, and less blood product use. Small potential cost and waste reductions were also achieved. This approach was performed safely with no unexpected adverse events.
- 22 April 2025
- Published by SAGE Publications in Perfusion
- Vol. 40 (1_suppl) , 15S-28S
Red blood cell transfusion in veno-arterial extracorporeal membrane oxygenation – the disconnect between oxygen delivery and tissue oxygenation
Background: Red cell transufion in veno-arterial membrane oxygenation (VA ECMO) has been widely debated. Purpose: This narrative review aims to examine the historical and current approaches of red cell transfusion in veno-arterial extracorporeal membrane oxygenation (VA ECMO) to enhance oxygen delivery. It will explore the potential benefits and pitfalls of red blood cell (RBC) transfusion in VA ECMO, including relationship between haemoglobin (Hb) concentration, tissue oxygenation and patient outcomes associated with transfusion. Following it will review the impact of cardiogenic shock on the microcirculation, performance of transfused RBC and effects of the ECMO circuit on RBC function. It will conclude with an introduction to potential mechanisms by which we might manipulate red cells to improve tissue oxygenation, without augmentation of Hb concentration. Conclusion: Further research is needed to provide insight into optimal RBC transfusion thresholds and strategies to augment red cell function to optimise tissue oxygenation in VA ECMO.
- 22 April 2025
- Published by SAGE Publications in Perfusion
- Vol. 40 (1_suppl) , 15S-28S
Red blood cell transfusion in veno-arterial extracorporeal membrane oxygenation – the disconnect between oxygen delivery and tissue oxygenation
Background: Red cell transufion in veno-arterial membrane oxygenation (VA ECMO) has been widely debated. Purpose: This narrative review aims to examine the historical and current approaches of red cell transfusion in veno-arterial extracorporeal membrane oxygenation (VA ECMO) to enhance oxygen delivery. It will explore the potential benefits and pitfalls of red blood cell (RBC) transfusion in VA ECMO, including relationship between haemoglobin (Hb) concentration, tissue oxygenation and patient outcomes associated with transfusion. Following it will review the impact of cardiogenic shock on the microcirculation, performance of transfused RBC and effects of the ECMO circuit on RBC function. It will conclude with an introduction to potential mechanisms by which we might manipulate red cells to improve tissue oxygenation, without augmentation of Hb concentration. Conclusion: Further research is needed to provide insight into optimal RBC transfusion thresholds and strategies to augment red cell function to optimise tissue oxygenation in VA ECMO.
- 31 December 2024
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 41 (4) , 605-612
Mechanical Circulatory Support for Septic Shock in Children and Adults: Different But Similar
- 31 December 2024
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 41 (4) , 605-612
Mechanical Circulatory Support for Septic Shock in Children and Adults: Different But Similar
- 27 December 2024
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 41 (4) , 621-629
The Role of Nitric Oxide in the Sweep Gas for Patients Receiving Extracorporeal Membrane Oxygenation or Cardiopulmonary Bypass
- 27 December 2024
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 41 (4) , 621-629
The Role of Nitric Oxide in the Sweep Gas for Patients Receiving Extracorporeal Membrane Oxygenation or Cardiopulmonary Bypass
- Open Access
- 26 December 2024
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 26 (3) , e374-e385
Resuscitation in Paediatric Septic Shock Using Vitamin C and Hydrocortisone (RESPOND): The RESPOND Randomized Controlled Trial Protocol
OBJECTIVES: Pediatric sepsis results in significant morbidity and mortality worldwide. There is an urgent need to investigate adjunctive therapies that can be administered early. We hypothesize that using vitamin C combined with hydrocortisone increases survival free of inotropes/vasopressors support until day 7 compared with standard care. Here we describe the Resuscitation in Paediatric Septic Shock using Vitamin C and Hydrocortisone (RESPOND) trial protocol, which aims to address this hypothesis. DESIGN: Randomized, open label, controlled, parallel-group, three-arm trial with integrated economic evaluation. SETTING: Nine Australia and New Zealand PICUs, with interest from additional international sites. PATIENTS: Children between 7 days and younger than 18 years old who are treated for suspected or confirmed sepsis and receiving inotropes/vasopressors for greater than 1 hour. INTERVENTIONS: IV vitamin C (100 mg/kg [maximum 5 g] every 6 hr) and hydrocortisone (1 mg/kg [maximum 50 mg] every 6 hr), or IV hydrocortisone alone (1 mg/kg [maximum 50 mg] every 6 hr) or standard care. MEASUREMENTS AND MAIN RESULTS: Three hundred eighty-four children will be randomly assigned to receive the interventions, or standard care in a 1:1:1 ratio with stratification by steroid administration pre-randomization and hospital site. The primary outcome is time alive and free of inotropes/vasopressors, censored at 7 days. Secondary outcomes include 28-day mortality, survival free of organ support, PICU length of stay, quality of life, functional status and neurodevelopmental vulnerability at 6 months post-enrollment, and hospitalization-related costs. Statistical analysis will be based on an intention-to-treat principle. The study has ethical approval (HREC/20/QCHQ/69922, dated December 21, 2020), is registered in the Australian New Zealand Clinical Trials Registry (ACTRN12621000247875), commenced recruitment on December 8, 2021, and is expected to finish recruitment by mid-2026. CONCLUSIONS: Dissemination of the results will occur through publication in peer-reviewed journals, presentations at international conferences, and additional consumer-informed pathways.
- 26 December 2024
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 26 (3) , e374-e385
Open AccessResuscitation in Paediatric Septic Shock Using Vitamin C and Hydrocortisone (RESPOND): The RESPOND Randomized Controlled Trial Protocol
OBJECTIVES: Pediatric sepsis results in significant morbidity and mortality worldwide. There is an urgent need to investigate adjunctive therapies that can be administered early. We hypothesize that using vitamin C combined with hydrocortisone increases survival free of inotropes/vasopressors support until day 7 compared with standard care. Here we describe the Resuscitation in Paediatric Septic Shock using Vitamin C and Hydrocortisone (RESPOND) trial protocol, which aims to address this hypothesis. DESIGN: Randomized, open label, controlled, parallel-group, three-arm trial with integrated economic evaluation. SETTING: Nine Australia and New Zealand PICUs, with interest from additional international sites. PATIENTS: Children between 7 days and younger than 18 years old who are treated for suspected or confirmed sepsis and receiving inotropes/vasopressors for greater than 1 hour. INTERVENTIONS: IV vitamin C (100 mg/kg [maximum 5 g] every 6 hr) and hydrocortisone (1 mg/kg [maximum 50 mg] every 6 hr), or IV hydrocortisone alone (1 mg/kg [maximum 50 mg] every 6 hr) or standard care. MEASUREMENTS AND MAIN RESULTS: Three hundred eighty-four children will be randomly assigned to receive the interventions, or standard care in a 1:1:1 ratio with stratification by steroid administration pre-randomization and hospital site. The primary outcome is time alive and free of inotropes/vasopressors, censored at 7 days. Secondary outcomes include 28-day mortality, survival free of organ support, PICU length of stay, quality of life, functional status and neurodevelopmental vulnerability at 6 months post-enrollment, and hospitalization-related costs. Statistical analysis will be based on an intention-to-treat principle. The study has ethical approval (HREC/20/QCHQ/69922, dated December 21, 2020), is registered in the Australian New Zealand Clinical Trials Registry (ACTRN12621000247875), commenced recruitment on December 8, 2021, and is expected to finish recruitment by mid-2026. CONCLUSIONS: Dissemination of the results will occur through publication in peer-reviewed journals, presentations at international conferences, and additional consumer-informed pathways.
- Open Access
- 26 December 2024
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 26 (3) , e315-e323
Hemostatic Outcome Definitions in Pediatric Extracorporeal Membrane Oxygenation: Challenges in Cohorts From Rotterdam (2019–2023) and Melbourne (2016–2022)
OBJECTIVES: To determine if a priori standardization of outcome hemostatic definitions alone was adequate to enable useful comparison between two cohorts of pediatric extracorporeal membrane oxygenation (ECMO) patients, managed according to local practice and protocol. DESIGN: Comparison of two separate prospective cohort studies performed at different centers with standardized outcome definitions agreed upon a priori. SETTING: General and cardiac PICUs at the Royal Children’s Hospital (RCH) in Melbourne, Australia, and the Sophia Children’s Hospital (SCH) in Rotterdam, The Netherlands. PATIENTS: Children (0–18 yr old) undergoing ECMO. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Although outcome definitions were standardized a priori, the interpretation of surgical interventions varied. The SCH study included 47 ECMO runs (September 2019 to April 2023), and the RCH study included 97 ECMO runs (September 2016 to Jan 2022). Significant differences in patient populations were noted. RCH patients biased toward frequent cardiac ECMO indications, central cannulation, and cardiopulmonary bypass before ECMO. The frequency of outcome ascertainment was not standardized. CONCLUSIONS: This international comparison shows that standardizing hemostatic outcome definitions alone is insufficient for sensible comparison. Uniform interpretation of definitions, consistent frequency of outcome ascertainment, and stratification based on patient populations and ECMO practices are required. Our results highlight the granularity of detail needed for cross-center comparison of hemostatic outcomes in pediatric ECMO. Further work is needed as we move toward potential multicenter trials of pediatric ECMO.
- 26 December 2024
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 26 (3) , e315-e323
Open AccessHemostatic Outcome Definitions in Pediatric Extracorporeal Membrane Oxygenation: Challenges in Cohorts From Rotterdam (2019–2023) and Melbourne (2016–2022)
OBJECTIVES: To determine if a priori standardization of outcome hemostatic definitions alone was adequate to enable useful comparison between two cohorts of pediatric extracorporeal membrane oxygenation (ECMO) patients, managed according to local practice and protocol. DESIGN: Comparison of two separate prospective cohort studies performed at different centers with standardized outcome definitions agreed upon a priori. SETTING: General and cardiac PICUs at the Royal Children’s Hospital (RCH) in Melbourne, Australia, and the Sophia Children’s Hospital (SCH) in Rotterdam, The Netherlands. PATIENTS: Children (0–18 yr old) undergoing ECMO. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Although outcome definitions were standardized a priori, the interpretation of surgical interventions varied. The SCH study included 47 ECMO runs (September 2019 to April 2023), and the RCH study included 97 ECMO runs (September 2016 to Jan 2022). Significant differences in patient populations were noted. RCH patients biased toward frequent cardiac ECMO indications, central cannulation, and cardiopulmonary bypass before ECMO. The frequency of outcome ascertainment was not standardized. CONCLUSIONS: This international comparison shows that standardizing hemostatic outcome definitions alone is insufficient for sensible comparison. Uniform interpretation of definitions, consistent frequency of outcome ascertainment, and stratification based on patient populations and ECMO practices are required. Our results highlight the granularity of detail needed for cross-center comparison of hemostatic outcomes in pediatric ECMO. Further work is needed as we move toward potential multicenter trials of pediatric ECMO.
- Open Access
- 17 December 2024
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 26 (1) , e122-e130
The Australian and New Zealand Intensive Care Society Paediatric Study Group (ANZICS PSG): 20 Years of Collaborative Research
- 17 December 2024
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 26 (1) , e122-e130
Open AccessThe Australian and New Zealand Intensive Care Society Paediatric Study Group (ANZICS PSG): 20 Years of Collaborative Research